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The most common etiologic agents causing chronic hepatitis are hepatitis C and B viruses (HCV and HBV,
respectively). Chronic infection caused by HCV is considered one of the major causative agents of liver cirrhosis and
hepatocellular carcinoma worldwide. In combination with the increasing rate of new HCV infections, the lack of a
current vaccine and/or an effective treatment for this virus continues to be a major public health challenge. The
development of new treatments requires a better understanding of the virus and its interaction with the different
components of the host cell. MicroRNAs (miRNAs) are small non-coding RNAs functioning as negative regulators of
gene expression and represent an interesting lead to study HCV infection and to identify new therapeutic targets.
Until now, microRNA-122 (miR-122) and its implication in HCV infection have been the focus of different published
studies and reviews. Here we will review recent advances in the relationship between HCV infection and miRNAs,
showing that some of them emerge in publications as challengers against the supremacy of miR-122.
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Nearly 20 years after their discovery, we now know that
microRNAs (miRNAs) modulate gene expression net-
works. These small non-coding RNAs (around 22
nucleotides) have been shown to function as regulators
of gene expression. First discovered in Caenorhabditis
elegans [1], miRNAs have quickly been considered a fun-
damental component of the regulatory system of gene
expression and have been estimated to control at least
one third of eukaryotic cell genes. miRNAs are tran-
scribed as long primary transcripts (pri-miRNAs) and
trimmed into approximately 70 nucleotide stem–loop
precursors (pre-miRNAs), most of the time by Drosha in
the nucleus [2]. Pre-miRNAs get exported to the cyto-
plasm by Exportin-5 and processed by Dicer to generate
mature miRNAs [3,4]. The mature miRNAs then direct
the binding of Argonaute-containing protein complexes
(RISC, for RNA-induced silencing complex) on specific* Correspondence: abengrine@biobanque-picardie.com
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reproduction in any medium, provided the ormessenger RNA (mRNA) targets to promote their deg-
radation or to affect their translation ([3] and Figure 1).
The 5' nucleotides, 2–7 of the mature miRNA, are called
the seed sequence and have the strongest influence for
target selection. miRNAs that share the same seed se-
quence are grouped into families, however they may not
have the same targets [5]. One miRNA has the ability to
target many different sites on the same mRNA or on
many different mRNAs.
Today, more than 1500 miRNAs have been identified
in the human genome (miRBase release 18 [6-8]), and
their biological functions are under investigation. Des-
pite the important advances accomplished to elucidate
their role in regulating different physiological and patho-
logical processes, our understanding of their implica-
tions in response to viral infection (hepatitis C virus for
instance) is in its early stages.
Hepatitis C virus (HCV) is a small enveloped positive-
strand RNA virus of the Flaviviridae family, classified in
the genus Hepacivirus. It infects around 3% of the world
population and it is the most common etiologic agent
underlying chronic hepatitis with hepatitis B virus
(HBV). Chronic HCV leads to cirrhosis of the liver and
ultimately to the development of hepatocellular carcin-
oma (HCC) [9]. Globally, 31.1% of HCC cases are causedral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Canonical miRNA biogenesis and function. miRNAs are transcribed as capped and polyadenylated primary transcripts (pri-miRNAs)
containing a hairpin structure that is excised by the endonuclease Drosha. This liberated stem-loop (pre-miRNA) is transported to the cytoplasm
by exportin 5 to be processed by the Dicer endonuclease. RNA-induced silencing complex (RISC) selectively handles one strand of the resulting
duplex and triggers target mRNA silencing through cleavage or translational repression.
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of HCC cases [10]. The prevalence of HCC, fifth in term
of frequency and third in term of mortality within can-
cers, demonstrates the enormous threat posed by HCV
infection to the worldwide public health. Moreover, anti-
HCV treatments show irregular efficiency between viral
genotypes and the ethnic origin of the infected patients.
One example of this irregularity is demonstrated in
patients who are infected with the type 1 genotype. They
typically only show 50% effectiveness when treated with
pegylated interferon (pegIFN) and ribavirin [11]. The rate
of sustained viral response (SVR) to treatment is
improved to 70% when antiproteases are associated with
this standard regimen [12]. Other combinations with
new molecules are expected to promote HCV eradication
in almost all patients regardless of the HCV genotype.
Recent advancements in understanding virus-host
interactions uncovered multiple host factors used by
HCV to infect cells [13]. As a major factor in controllingdifferent cellular processes, miRNAs represent an inter-
esting field of investigation regarding HCV infection and
replication. Furthermore, they may represent new targets
for the development of antiviral therapeutics. The work
of Yang et al. provides a proof of concept for the poten-
tial use of these molecules. Indeed, these authors showed
that HCV replication in vitro and in a mouse model was
inhibited when 5 artificial anti-HCV miRNAs, cloned in
the miR-17-92 cluster and delivered by an adenovirus
vector, are expressed [14]. These 5 artificial miRNAs
reduced the replication of cell culture-propagated HCV
(HCVcc) by 98% and resulted in 93% HCV gene silen-
cing in mouse livers without causing any hepatocellular
toxicity. However, these results should be taken with
caution as it has also been shown that over-expression
of certain pre-miRNA-like molecules in the liver is lethal
in mice [15]. Recently, Berezhna et al. reported that rep-
lication or suppression of HCV RNA depends on the
interaction of Ago2 protein (member of RISC complex)
Table 1 Summary of the matches implied in HCV
inhibition by 3 microRNAs considered as potential
therapeutic targets
microRNA Inhibition of HCV infection by
Matches on HCV RNA Matches on host targets
miR-196b NS5A coding region
(6680) [27]
Bach1 3’UTR (2286 and
2166) [35]
miR-199a-3p 5’UTR IRES (60) [26] NR
miR-29 NR NR
The numbers in brackets indicate the first nucleotide of the binding sites of
the miRNAs.
UTR: untranslated region; IRES: internal ribosome entry site; NR: non reported.
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partitioning to different cell compartments [16]. This
finding is an additional proof in favor of the therapeutic
potential of miRNAs.
Since the first publication reporting the positive role
of miR-122 in HCV replication [17], this liver-specific
miRNA has been a focus of numerous research projects
investigating the liver and HCV interaction. It has 4
binding sites in the HCV genome [18], it is implicated in
regulation of different metabolic pathways in liver cells
(cholesterol metabolism) [19] and it represents 50% to
70% of all the miRNAs expressed in the liver [20-22]. An
anti-HCV treatment based on miR-122 inhibition by
antisense oligonucleotides has been tested on chimpan-
zees and provided very promising results [23]. The same
anti-miR-122 molecule is also the first miRNA-targeting
treatment to enter into human clinical trials (currently
in phase 2) to treat patients infected with HCV (miravir-
sen, Santaris Pharma A/S). Even though miR-122 has
been the most studied miRNA in HCV infection and the
clinical trials using anti-miR-122 have shown promising
results against HCV, this strategy against miR-122 might
have some negative impacts on the hepatocytes’ metab-
olism. Therefore, other miRNAs may also play an im-
portant role in HCV-host interactions and be good
candidates for the fight against HCV. This is the reason
why several research teams around the world are inter-
ested in bringing to light the whole “miRNome” and un-
cover the role played by other miRNAs in controlling
such interactions. Randall et al. reported a systematic
RNA interference (RNAi) screening study on the human
hepatoma cell line Huh-7.5 [24]. In this work they tar-
geted 62 cellular genes, using siRNAs thought to play a
role in HCV infection, and demonstrated that RNAi tar-
geted 26 of these genes and reduced viral production by
at least 3 fold. Some of these siRNAs targeted Dicer or
other components of the RNAi pathway, therefore con-
firming the close interaction between HCV and the
miRNA machinery. Other studies reported specific miR-
NAs altering HCV infection and/or being altered by the
presence of the virus. It is reasonable to assume that
some of these miRNAs may have a promising potential
as therapeutic targets, such as miR-196b, miR-199a-3p
and miR-29 that inhibit HCV replication in several mod-
els [25-27]. Despite this promising potential, these miR-
NAs are not as intensively studied as miR-122 [28-30].
In this review, we will therefore discuss recent
advances in the relationship between HCV infection and
miRNAs and show that some of them might be as im-
portant as miR-122 in the fight against HCV.
miR-196b
The mir-196 gene family contains 3 members (mir-196a-
1, -196a-2, and -196b) and are found in the homeoboxclusters of vertebrates [31]. Two mature miRNA, miR-
196a and miR-196b, differing by only one nucleotide, are
products of these 3 genes [31]. miR-196 was first
reported to have extensive and evolutionarily conserved
complementarity to homeobox clusters and to regulate
the expression of homeobox genes such as HoxB8 [32].
In addition to its role in development, many studies on
miR-196 reported its role in several cancers (for review,
see [31]). The increased expression of miR-196b in HCC
when compared with normal livers [33] suggests that
this miRNA may have an oncogenic role in HCC.
It has been reported that miR-196b has a target site in
the NS5A coding region of HCV RNA (Table 1 and
[27]). The expression of miR-196b and eight other miR-
NAs predicted to target HCV RNA is modulated upon
interferon (IFN) β treatment of primary mouse hepato-
cytes and Huh7 cells [27]. Because IFNβ significantly
affects the innate anti-HCV response, the authors tested
the impact of these IFNβ-induced miRNAs on HCV rep-
lication. Only 5 miRNAs decreased HCV replication, in-
cluding miR-196b and an antisense oligonucleotide
against miR-122. The decrease of HCV replication ran-
ged from 50% to 80% (60% for miR-196b). Later,
Scagnolari et al. confirmed the increase of miR-196b ex-
pression by the IFN pathway in human peripheral blood
mononuclear cells (PBMC) of healthy individuals [34].
The mechanisms involved in the inhibition of HCV
replication by miR-196b were later revealed by Hou
et al. (Figure 2). In addition to the direct targeting of the
HCV RNA, Bach1, a repressor of the anti-oxidative and
anti-inflammatory heme oxygenase 1 (HMOX1), is also
a direct target of miR-196b [35]. In this study, this
miRNA was able to inhibit HCV expression in replicon
cell lines (around 50% of inhibition) directly by targeting
HCV RNA and indirectly by increasing HMOX1 expres-
sion. Evidence suggests that the importance of Bach1
targeting is predominant over direct HCV targeting,
however the mechanisms of HCV inhibition by HMOX1
remain unknown. As HCV infection causes oxidative
stress and miR-196b inversely modulates HCV replica-
tion and HMOX1 expression, overexpression of miR-
Figure 2 miR-196b and hepatitis C virus infection. After
activation by hepatitis C virus (HCV) infection, interferon (IFN)
pathway stimulates the expression of miR-196b. This miRNA inhibits
HCV replication either directly via a target site on the HCV RNA or
indirectly via Bach1 down-regulation and heme oxygenase-1
(HMOX1) up-regulation. The indirect pathway seems to be
predominant. How HCV responds to miR-196b targeting remains to
be fully investigated.
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liver injury during chronic hepatitis. Interestingly, miR-
122 has also been linked to the down-regulation of
HMOX1 [36], which means that the overexpression of
miR-196b could be even more efficient if associated with
inhibition of miR-122 [36].
It is unknown whether HCV has evolved to counteract
the effect of this antiviral miRNA, although some studies
suggest that such a mechanism might exist. Indeed, the
expression of miR-196a and miR-196b decreases upon
HCV transfection of HepG2 cells as well as in PBMC of
chronic hepatitis C patients [34,37]. This decrease could
be linked to the inhibition of IFN pathway by the virus,
since in PBMCs from chronic hepatitis C patient the ex-
pression of miR-196b does not change after IFNα treat-
ment, whereas it is increased in PBMCs from healthy
controls [34]. However these results remain to be for-
mally proven, as it has been shown in one study that
miR-196b and miR-196a seem to be respectively
increased and decreased in HCV replicon-containing cell
lines [38]. Furthermore, Grek et al. reported in anotherstudy that miR-196b was increased in PBMC replicating
HCV [39]. HCV infection and replication in PBMCs still
remains controversial, but these results suggest that the
interactions between miR-196b and HCV infection are
complex. These discordances might also be evidence of
the limitations of cell lines and replicons against primary
cells and complete virus cycle, respectively. In the light
of these data, it could be hypothesized that miR-196b
expression is (i) induced by the IFN pathway in cells
replicating HCV and (ii) decreased by the pro-viral
mechanisms, although this has yet to be verified.
miR-199a-3p
According to miRBase release 18 [6-8], the miR-199
family is derived from 3 genes: mir-199a-1, -199a-2 and
-199b. In terms of read number, the functional mature
miRNA appear to be the 3p form for both miR-199a and
miR-199b. Several studies reported an anti-tumoral role
for miR-199a-3p, which targets the proliferation and mi-
gration/invasion signaling pathways in different cancers,
especially HCC [22,40-42]. Others suggested that miR-
199a-3p anti-tumoral activity is not associated with a
specific cancer [43]. miR-199a-3p has also been asso-
ciated with liver fibrosis progression [44] and alcoholic
or nonalcoholic liver injuries [45].
In the context of viral infection, miR-199a-3p has been
identified as a broadly active antiviral miRNA against
members of all three herpesvirus subfamilies and the
positive sense RNA virus Semliki Forest virus [46]. In
this study, miR-199a-3p modulated the signaling
pathways involved in viral replication such as PI3K/AKT
and ERK/MAPK. The identification of miR-199a-3p
binding sites in the 5’UTR IRES of HCV RNA
(genotypes 1b and 2a) [26] suggested a direct interaction
between these molecules (Table 1). Furthermore, overex-
pression of miR-199a-3p has an 80-90% inhibitory effect
on virus replication, whereas viral replication and pro-
tein expression are promoted by the suppression of miR-
199a-3p [26]. In the same study, Murakami et al. showed
that miR-199a-3p induced viral RNA accumulation in
the RISC complex as a consequence of direct binding to
the 5’UTR IRES and was independent from the IFN
pathway. Later, the same researchers showed that
increased miR-199a-3p expression (with 34 other miR-
NAs) was associated with SVR in chronic hepatitis C
patients when compared with non-SVR [47]. However, it
remains to be investigated whether this miRNA inhibits
HCV replication by direct binding to the viral RNA and/
or indirectly via the negative regulation of cellular fac-
tors. It is worth noting that HBV replication is also
inhibited by miR-199a-3p, as a consequence of direct
interaction of the miRNA and the HBV coding region
[48]. According to these pieces of evidence, the miR-
199a-3p mechanism of action could be summarized as
Figure 3 miR-199a-3p and hepatitis C virus infection. miR-199a-
3p shows antiviral activity by directly interacting with HCV RNA and
by inhibiting its replication, which increases the chance of a
sustained viral response to antiviral treatment. miR-199a-3p might
also exert an indirect inhibition of HCV via signaling pathways, as it
were reported for other viruses. How this relates to the fact that HCV
stimulates miR-199a-3p expression remains to be shown.
Figure 4 miR-29 and hepatitis C virus infection. miR-29 inhibits
hepatitis C virus (HCV) replication in hepatocytes, maybe via
cyclooxygenase-2 (COX-2) and IFN lambda (IFNλ), while at the same
time HCV also inhibits miR-29 expression in hepatocytes to increase
its replication. In hepatic stellate cells, miR-29 regulates the synthesis
of the extracellular matrix (ECM), thus it inhibits fibrosis. HCV
infection increases injury-associated TGFβ production, which inhibits
miR-29 expression in stellate cells. This deregulates ECM synthesis
and leads to fibrosis.
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major role in the hepatic antiviral response.
With such a strong effect on HCV replication, we
could assume that miR-199a-3p expression is modified
during HCV infection. In the numerous studies report-
ing miRNA expression profiles in HCV-infected cells or
tissues, only two demonstrated an impact on miR-199a-
3p by showing that the expression of this miRNA was
increased during HCV infection [49,50]. It should also
be noted that this miRNA is only weakly expressed in
the liver [26], which means that further investigations
are needed to fully assess the significance of the miR-
199a-3p antiviral effect against HCV, as well as how
HCV infection modulates the expression of this miRNA.
miR-29
The miR-29 family comprises 3 members: miR-29a, -29b,
and -29c, which are expressed from 4 genes, mir-29a, -29b-1,
-29b-2 and 29c (miRBase release 18 [6-8]). To date
miR-29 members have been implicated in the fibrosis of
different organs such as the liver [51], kidney [52], heart
[53] and lung [54]. Furthermore, miR-29 was also
associated with IFNγ production [55]. These miRNAs
appear to have tumor suppressor activity in leukemia [56]
and HCC [57,58], as well as an antiviral activity against
HBV [57].
The relationship between HCV infection and miR-29
family expression in hepatocytes and hepatic stellate
cells (HSC) has been recently reported [25]. The analysis
of miRNA profiles of HCVcc-infected Huh-7.5 cells and
livers from chronic hepatitis C patients showed a 2-fold
decrease of the 3 members of the miR-29 family com-
pared to controls. The activation of HSCs also leads to
the down-regulation of miR-29. Moreover, the same
study showed that over expression of miR-29 in infected
Huh-7.5 cells resulted in a 70% decrease of HCV replica-
tion. The over expression of miR-29 in HSCs inhibitedtheir proliferation and their collagen production. Cur-
rently the mechanism explaining how HCV infection
triggers the down-regulation of miR-29 in hepatocytes is
unknown. It can be hypothesized that in HSCs the miR-
29 down regulation is activated by liver injury-induced
TGFβ along with the increased extracellular matrix pro-
duction, which ultimately leads to fibrosis (Figure 4). Re-
cently, the activation of cyclooxygenase-2 and IFN
lambda production have been reported as mechanisms
involved in the miR-29 antiviral activity against influenza
virus [59]. This pathway has yet to be explored regarding
HCV infection.
Others have documented the link between miR-29
family members and HCV infection. These studies
showed the expression of miR-29a decreases in HCVcc-
infected Huh-7.5 cells [60], and miR-29c is down regu-
lated both in livers of patients presenting viral hepatitis
(HCV or HBV) [61] and in livers presenting HCV-
associated HCC [62]. Furthermore, in livers from
chronic hepatitis C patients presenting SVR, miR-29a,
-29b and -29c levels increased when compared to livers
of patients without SVR [47]. This finding suggests that
the miR-29 family (probably in combination with other
miRNAs) could be a useful biomarker when monitoring
the response to anti-HCV treatments.
Altogether there is a growing body of evidence sug-
gesting the importance of the miR-29 family’s role in the
cells’ defense against HCV and a treatment with miR-29
might inhibit HCV while reducing fibrosis.
Other promising miRNAs
Several other miRNAs have been recently reported as
associated with HCV infection, either because they
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(Figure 5). For instance, the expression of miR-141 is
increased in HCV-transfected primary human hepato-
cytes when cocultured with a rat hepatic stellate cell line.
Also observed was stimulated virus replication and pro-
duction [49]. According to the same study, miR-141-
mediated HCV stimulation involves the direct inhibition
of the tumor-suppressor DLC-1.
By inhibiting the PI3K/Akt pathway, miR-491
stimulates HCV replication in replicon or HCVcc-
infected Huh-7 cells [63]. This inhibition does not
depend on the viral genotype, cell proliferation or HCV
IRES activity. In HCV-infected Huh7 cells, miR-491
expression is increased during the first 4 days post-
infection (up to 12 fold) [60], before going down after
the fifth day [63]. Moreover, it is established that
miR-491 also induces apoptosis [64]. These data suggest
that miR-491 is involved in the early steps of HCV infec-
tion followed by a decrease in its expression, which
might favor the development of HCC. Other interesting
findings were reported by Ishida et al., who demon-
strated a stimulatory effect of miR-192 and −215 on
HCV replication [63].
Meanwhile, the induction of miR-296 by IFNβ directly
inhibits HCV replication in infected Huh7 cells by dir-
ectly targeting the viral RNA [27]. Furthermore, the ex-
pression of miR-296 is decreased in the liver and
increased in PBMCs of HCV-infected patients [34,50].
These findings suggest an unknown and complex set of
mechanisms and interactions between HCV and miR-296.
As for miR-196b, the expression of miR-351, -431 and
−448 is induced by IFNβ, thus these miRNAs may pos-
sess an inhibitory effect on HCV replication through dir-
ect targeting of the viral RNA [27]. The expression of
miR-130, -146, -200, -192 and −194 is modified by HCV
infection in several models as reported by differentFigure 5 Other promising miRNAs associated with hepatitis C
virus infection. Some miRNAs are altered by hepatitis C virus (HCV)
infection and appear as potential biomarkers, or are simply altered
by the virus. Others are reported as altering HCV replication. Four
miRNAs are both altered by HCV and alter its replication.studies [37,38,49,50,60,63,65]. Interestingly, miR-192 and
−194 are liver-specific miRNAs [66,67] and are asso-
ciated with SVR in chronic hepatitis C patients [47]. Fi-
nally, miR-21, which is associated with liver regeneration
[68] and HCC [69], is increased in HCV-infected livers
and Huh-7.5 cells [50,70]. At least two studies have
showed a correlation between miR-21 increased expres-
sion and (i) SVR [47], (ii) viral load, (iii) fibrosis (via in-
hibition of SMAD7), and (iv) level of transaminases in
serum [70].
All these miRNAs represent promising targets for anti-
viral treatments and as potential biomarkers of HCV in-
fection and its outcome. Further investigations will be
required to fully characterize their cellular targets and
their modes of action.
Conclusions
There are now numerous pieces of evidence demon-
strating the therapeutic potential of miRNAs during
chronic HCV infection. Currently, miR-122 is the only
miRNA tested in therapeutic clinical trials designed to
treat HCV-infected chimpanzees [23] or human (San-
taris, phase 2). Other miRNAs, especially miR-196b, -
199a-3p and the miR-29 family, may possibly emerge
as very promising targets for anti-HCV treatments.
Based on the combination of all these miRNAs a new
anti-HCV therapy could be proposed as follows: anti-
miR-122, and mimics for miR-196b, miR-199a-3p and
miR-29. This combination could also be used in con-
junction with standard treatments to increase their ef-
ficiency. Such a protocol might have the advantage of
preserving patients from HCV replication and from
HCV-mediated injuries.
Due to miRNAs having multiple targets and their abil-
ity regulate different signaling pathways, it will be im-
portant to fully characterize their mechanisms of action
and their cellular targets in order to avoid any negative
patient outcomes. To date no serious adverse effect of
miR-122 inhibition has been observed in chimpanzees
[23] or healthy volunteers (Santaris, phase 2), however
long term studies will need to be completed to ensure
that over-expressed or blocked miRNAs don’t cause
more damage than they prevent.
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